SCHEMBL5380141

SCHEMBL5380141

N#CC1(c2ccc(Br)cc2Cl)CCN(C(=O)O)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.40
STING1 Q86WV6 2/20 0.36
RECQL P46063 1/20 0.36
MAPT P10636 1/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
OPRM1 P35372 1/20 0.36
SLC22A12 Q96S37 1/20 0.35
CA7 P43166 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CYP3A4 P08684 1/20 0.35
UGCG Q16739 1/20 0.35
OPRL1 P41146 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3994253 0.82 WDR5 (0.36) STING1OPRM1OPRL1WDR5
SCHEMBL2381444 0.78 CA12 (0.50) SMN1; SMN2CA12CA1CA2CA9
SCHEMBL3494228 0.76 CA12 (0.49) CA12CA1CA2CA9OPRM1
SCHEMBL1660328 0.76 CA12 (0.45) CA12CA1CA2CA9OPRM1
SCHEMBL12369419 0.75 HTR2C (0.35) STING1OPRM1WDR5
SCHEMBL2270629 0.75 MAPK10 (0.45) MAPT
SCHEMBL7656129 0.74 ADRA1A (0.43) CA12CA1CA2CA9CA7
SCHEMBL11963149 0.74 KDM4E (0.38) SMN1; SMN2CA12CA1CA2CA9
Hydrochloric Acid SCHEMBL2272245 0.74 OPRM1 (0.34) OPRM1WDR5
SCHEMBL23210895 0.73 CA12 (0.36) SMN1; SMN2CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP claimed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US claimed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP claimed
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 SMN1; SMN2 4550/4885STING1 3784/4885RECQL 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.